ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Elevated Serum Leptin Concentrations in a Subset of Fibromyalgia Patients with High Inflammatory Markers

Anne Quismorio1, John Solyman2, Lisa Asfahani3 and Samy Metyas4, 1Rheumatology, Covina Arthritis, Covina, CA, 2Research Associate, Covina, CA, 3Covina Arthritis, Covina, CA, 4University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, Covina, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers and fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus

Session Type: Abstract Submissions (ACR)

Background/Purpose

Previous studies suggest heterogeneity in the presentation of fibromyalgia (FM) with differences in biological variables including elevated sedimentation rate (ESR), cytokine profile, and hormone levels. Whether these variables identify subgroups within FM population remains to be established. We have previously reported primary FM patients with elevated inflammatory markers( Metyas SK, et al. Ann Rheum Dis, 2007;66(Suppl II):625.)

The diagnosis of FM is largely clinical, and specific biomarkers have yet to be identified. Vectra®DA is a multi-biomarker disease activity score, validated to measure disease activity in rheumatoid arthritis (RA).  It is a commercially available test designed to measure serum concentrations of 12 biomarkers in RA.

The purpose of the study is to measure biomarkers using the Vectra®DA in FM patients with elevated inflammatory markers.

Methods

A cross-sectional, prospective study of 33 patients seen in an outpatient-based rheumatology practice in Los Angeles County was undertaken.   Each met the 2010 ACR classification criteria for FM and had elevated ESR and/or CRP.  None had clinical evidence of RA or other systemic rheumatic disease. Tests were negative for rheumatoid factor, anti-CCP antibodies, and HLA-B27. Serum specimens were tested using the Vectra®DA.

Results

Mean age was 43.5 years, 94% were female and 6% were male.  The Vectra®DA was elevated for all patients with a mean score of 46.5 (range 30 to 84, or moderate to high activity).  Among the twelve biomarkers (including IL-6 and CRP) serum concentrations were within the range reported in RA except leptin. 45% of subjects had leptin concentrations exceeding the range reported in RA (1-45 ng/mL). The mean leptin was 42.3 ng/mL (range 30-81 ng/mL).

There was a positive correlation between leptin concentration and BMI in the entire cohort; however, this correlation was not observed in the patient subgroup with leptin levels above the range in RA (P= 0.6).  CRP but not ESR was positively correlated with the Vectra®DA score.

Conclusion

We have identified a subset of FM patients with elevated ESR and/or CRP. The elevated Vectra®DA scores support the concept of an associated  inflammatory process in this subset of patients. The elevated levels of leptin in this subset, independent of BMI, suggest that factors other than obesity may account for this elevation.  The emerging evidence that leptin plays a significant pro-inflammatory and immunomodulatory role warrants further investigation in the pathogenesis of this clinical subset of FM. Understanding this clinical subset may lead to different diagnostic and therapeutic strategies in FM.


Disclosure:

A. Quismorio,
None;

J. Solyman,
None;

L. Asfahani,
None;

S. Metyas,

Crescendo Bioscience,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-serum-leptin-concentrations-in-a-subset-of-fibromyalgia-patients-with-high-inflammatory-markers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology